Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: A randomized study

European Journal of Haematology

Volumn 88, Issue 6, 2012, Pages 485-496

  Hjorth, Martin ^a   Hjertner, Øyvind ^b   Knudsen, Lene Meldgaard ^c   Gulbrandsen, Nina ^d   Holmberg, Erik ^e   Pedersen, Per Trøllund ^c,f   Andersen, Niels Frost ^g   Andréasson, Björn ^h,s   Billström, Rolf ⁱ   Carlson, Kristina ^j   Carlsson, Margaretha S ^k   Flogegård, Max ^l   Forsberg, Karin ^m   Gimsing, Peter ^n,ab   Karlsson, Torbjörn ^j,u,v   Linder, Olle ^o   Nahi, Hareth ^p,t   Othzén, Annika ^q   Swedin, Agneta ^r   Jerner, Annika Othzén ^q   Lenhoff, Stig ^r   Axelsson, Per ^w   Lundqvist, Kjell ^x   Larsson, Gun ^y   Holm, Elena ^r   Kristoffersson, Rose Marie ^z   Blimark, Cecilie ^z   Strandberg, Maria ^aa   Vangsted, Annette ^ac   Gregersen, Henrik ^ad   Schjesvold, Fredrik ^ae   Haukås, Einar ^af   more..

^a Lidkoping Hospital   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^f University of Esbjerg   (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h Hematology Section   (Sweden)

ⁱ Department of Medicine   (Sweden)

^j UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^k Vaxjo Hospital   (Sweden)

^l FALUN HOSPITAL   (Sweden)

^m UMEÅ UNIVERSITY HOSPITAL   (Sweden)

ⁿ UNIVERSITY OF COPENHAGEN   (Denmark)

^o ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^p KAROLINSKA INSTITUTE   (Sweden)

^q GÄVLE HOSPITAL   (Sweden)

^r LUND UNIVERSITY HOSPITAL   (Sweden)

^s UDDEVALLA HOSPITAL   (Sweden)

^t KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^u Vasteras Hospital   (Sweden)

^v ST GÖRAN S HOSPITAL   (Sweden)

^w HELSINGBORG HOSPITAL   (Sweden)

^x Ornskoldsviks Hospital   (Sweden)

^y BLEKINGE HOSPITAL   (Sweden)

^z SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^aa SUNDSVALL HOSPITAL   (Sweden)

^ab Rigshospitalet   (Denmark)

^ac GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^ad AALBORG UNIVERSITY HOSPITAL   (Denmark)

^ae Diakonhjemmet   (Norway)

^af STAVANGER UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

Bortezomib; Multiple myeloma; Quality of life; Randomized trial; Thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOMA; NEUROPATHY; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CROSS-OVER STUDIES; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; QUALITY OF LIFE; RECURRENCE; THALIDOMIDE;

EID: 84861198392     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01775.x     Document Type: Article

References (28)

1. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006;132:410-51.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
3. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584-93.
4. Von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, Hoffmann F, Naumann R, Bargou R, Cook G, Glasmacher A. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008;81:247-52.
5. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
6. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
7. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
8. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
9. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). National Cancer Institute, 2007.
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
11. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44.
12. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010;11:934-41.
13. Mateos MV. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 2011;12:410-1.
14. Chanan-Khan A, Sonneveld P, Schuster MW, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784-90.
15. Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229-32.
16. Offidani M, Corvatta L, Marconi M, et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004;5:312-7.
17. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
18. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.
19. Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis 2008;25:224-6.
20. Martin MG, Vij R. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature. Clin Lymphoma Myeloma 2009;9:320-3.
21. Kristinsson SY, Pfeiffer RM, Bjorkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 2010;115:4991-8.
22. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
23. Kristinsson SY. Thrombosis in multiple myeloma. Hematology Am Soc Hematol Educ Program 2010;2010:437-44.
24. Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br J Haematol 1996;94:324-32.
25. Gulbrandsen N, Wisloff F, Brinch L, et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Med Oncol 2001;18:65-77.
26. Kvam AK, Fayers P, Wisloff F. What changes in health-related quality of life matter to multiple myeloma patients? A prospective study Eur J Haematol 2010;84:345-53.
27. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
28. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007;20:625-35.